REGENERON PHARMACEUTICALS INC (NASDAQ: REGN)

REGENERON PHARMACEUTICALS INC

NASDAQ: REGN (Regeneron Pharmaceuticals, Inc.)

Last update: 4 days ago, 9:22AM

750.40

24.19 (3.33%)

Add to watchlist

Previous Close	726.21
Open	726.98
Volume	184,509
Avg. Volume (3M)	1,101,198
Market Cap	79,532,867,584

Price / Earnings (TTM)	18.00
Price / Earnings (Forward)	17.45
Price / Sales	5.73
Price / Book	2.52

52 Weeks Range	476.49 (-36%) — 790.98 (5%)
Earnings Date	28 Oct 2025
TTM Dividend Yield	0.47%

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Mixed	Mixed
	Biotechnology (Global)	Mixed	Mixed
Stock	Regeneron Pharmaceuticals, Inc.	Bearish	Bearish

AIStockmoo Score

0.0

Analyst Consensus	-0.5
Insider Activity	-4.0
Price Volatility	-0.5
Technical Moving Averages	2.5
Technical Oscillators	2.5
Average	0.00

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
REGN	80 B	0.47%	18.00	2.52
VRTX	116 B	-	31.86	6.62
ROIV	15 B	-	-	3.23
BMRN	10 B	-	19.82	1.70
MRUS	7 B	-	-	9.43
ABVX	10 B	-	-	8.74

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Sector	Healthcare
Industry	Biotechnology
Investment Style	Large Value
% Held by Insiders	1.89%
% Held by Institutions	91.98%

52 Weeks Range	476.49 (-36%) — 790.98 (5%)
Price Target Range	627.00 (-16%) — 1,057.00 (-99%)
High	1,057.00 (Canaccord Genuity, 40.86%)	Buy
Median	768.00 (2.35%)
Low	627.00 (B of A Securities, -16.44%)	Sell
Average	782.92 (4.33%)
Total	7 Buy, 5 Hold, 1 Sell
Avg. Price @ Call	701.50

Firm	Date	Target Price	Call	Price @ Call
Morgan Stanley	12 Dec 2025	768.00 (2.35%)	Hold	741.29
Morgan Stanley	03 Dec 2025	767.00 (2.21%)	Hold	723.67
Wells Fargo	10 Dec 2025	745.00 (-0.72%)	Hold	726.21
Wells Fargo	20 Nov 2025	700.00 (-6.72%)	Hold	737.00
BMO Capital	04 Dec 2025	850.00 (13.27%)	Buy	722.80
Canaccord Genuity	04 Dec 2025	1,057.00 (40.86%)	Buy	722.80
Canaccord Genuity	23 Oct 2025	850.00 (13.27%)	Buy	575.69
HSBC	24 Nov 2025	890.00 (18.60%)	Buy	761.45
Scotiabank	24 Nov 2025	770.00 (2.61%)	Hold	761.45
Truist Securities	24 Nov 2025	798.00 (6.34%)	Buy	761.45
UBS	07 Nov 2025	660.00 (-12.05%)	Hold	657.53
B of A Securities	29 Oct 2025	627.00 (-16.44%)	Sell	652.91
Cantor Fitzgerald	29 Oct 2025	740.00 (-1.39%)	Buy	652.91
Citigroup	29 Oct 2025	700.00 (-6.72%)	Buy	652.91
Citigroup	13 Oct 2025	660.00 (-12.05%)	Buy	557.73
Guggenheim	29 Oct 2025	865.00 (15.27%)	Buy	652.91
RBC Capital	29 Oct 2025	708.00 (-5.65%)	Hold	652.91
Show more

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
FENIMORE CHRISTOPHER R.	718.36	703.26	2,035	1,476,842
LAROSA JOSEPH J	718.36	703.26	1,080	796,908
MCCOURT MARION	718.36	697.92	119	131,980
MURPHY ANDREW J	718.36	697.92	-2,213	-1,455,052
PITOFSKY JASON	718.36	703.26	1,075	787,171
SCHLEIFER LEONARD S	-	692.58	-155,145	-107,450,324
VAN PLEW DANIEL P	718.36	697.92	-743	-439,170
YANCOPOULOS GEORGE	-	692.58	-131,874	-91,333,295
Aggregate Net Quantity				-285,666
Aggregate Net Value ($)				-197,484,941
Aggregate Avg. Buy ($)				718.36
Aggregate Avg. Sell ($)				698.41

Name	Holder	Date	Type	Quantity	Price	Value ($)
SCHLEIFER LEONARD S	Officer	09 Dec 2025	Disposed (-)	155,145	692.58	107,450,324
SCHLEIFER LEONARD S	Officer	09 Dec 2025	Option execute	172,723	-	-
YANCOPOULOS GEORGE	Officer	09 Dec 2025	Disposed (-)	131,874	692.58	91,333,295
YANCOPOULOS GEORGE	Officer	09 Dec 2025	Option execute	146,815	-	-
MCCOURT MARION	Officer	09 Dec 2025	Disposed (-)	1,021	692.58	707,124
MURPHY ANDREW J	Officer	09 Dec 2025	Disposed (-)	4,229	692.58	2,928,921
VAN PLEW DANIEL P	Officer	09 Dec 2025	Disposed (-)	2,552	692.58	1,767,464
FENIMORE CHRISTOPHER R.	Officer	08 Dec 2025	Disposed (-)	992	703.26	697,634
LAROSA JOSEPH J	Officer	08 Dec 2025	Disposed (-)	1,396	703.26	981,751
MCCOURT MARION	Officer	08 Dec 2025	Disposed (-)	1,336	703.26	939,555
MURPHY ANDREW J	Officer	08 Dec 2025	Disposed (-)	1,699	703.26	1,194,839
VAN PLEW DANIEL P	Officer	08 Dec 2025	Disposed (-)	1,906	703.26	1,340,414
PITOFSKY JASON	Officer	08 Dec 2025	Disposed (-)	989	703.26	695,524
FENIMORE CHRISTOPHER R.	Officer	05 Dec 2025	Acquired (+)	3,027	718.36	2,174,476
LAROSA JOSEPH J	Officer	05 Dec 2025	Acquired (+)	2,476	718.36	1,778,659
MCCOURT MARION	Officer	05 Dec 2025	Acquired (+)	2,476	718.36	1,778,659
MURPHY ANDREW J	Officer	05 Dec 2025	Acquired (+)	3,715	718.36	2,668,707
VAN PLEW DANIEL P	Officer	05 Dec 2025	Acquired (+)	3,715	718.36	2,668,707
PITOFSKY JASON	Officer	05 Dec 2025	Acquired (+)	2,064	718.36	1,482,695
Show more

Date	Type	Details
07 Dec 2025	Announcement	Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
01 Dec 2025	Announcement	Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
01 Dec 2025	Announcement	Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
25 Nov 2025	Announcement	Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
19 Nov 2025	Announcement	EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications
19 Nov 2025	Announcement	Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation
13 Nov 2025	Announcement	Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
08 Nov 2025	Announcement	Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
07 Nov 2025	Announcement	Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
03 Nov 2025	Announcement	Regeneron Announces Investor Conference Presentations
31 Oct 2025	Announcement	Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
29 Oct 2025	Announcement	OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications
28 Oct 2025	Announcement	Regeneron Reports Third Quarter 2025 Financial and Operating Results
17 Oct 2025	Announcement	Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
15 Oct 2025	Announcement	Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
12 Oct 2025	Announcement	DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
08 Oct 2025	Announcement	Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
30 Sep 2025	Announcement	Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
26 Sep 2025	Announcement	Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
22 Sep 2025	Announcement	Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
19 Sep 2025	Announcement	Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
17 Sep 2025	Announcement	Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
17 Sep 2025	Announcement	Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
Show more

TTM Dividend Yield	0.47%
Payout Ratio	2.24%
Expected Next Dividend Payment	Mar 2026

Ex Date	Announcement Date	Payment Date	Details
20 Nov 2025	-	05 Dec 2025	0.88 Cash
18 Aug 2025	-	03 Sep 2025	0.88 Cash
20 May 2025	-	06 Jun 2025	0.88 Cash
20 Feb 2025	-	20 Mar 2025	0.88 Cash

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	3.52	4	0.47

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	31.94%
Operating Margin (TTM)	19.94%
Diluted EPS (TTM)	39.36
Quarterly Revenue Growth (YOY)	-3.70%
Quarterly Earnings Growth (YOY)	12.00%

Total Debt/Equity (MRQ)	9.20%
Current Ratio (MRQ)	4.93
Operating Cash Flow (TTM)	3.95 B
Levered Free Cash Flow (TTM)	2.08 B

Return on Assets (TTM)	6.91%
Return on Equity (TTM)	15.96%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)